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Abstract
Objective—In angiogenesis, circulating mononuclear cells are recruited to vascular lesions; 
however, the underlying mechanisms are poorly understood.
Approach and Results—Here, we characterize the functional role of protein tyrosine kinase 7 
(PTK7)-expressing CD11b+ mononuclear cells in vitro and in vivo using a mouse model of 
angiogenesis. While the frequencies of PTK7+CD11b+ cells in the bone marrow remained similar 
after vascular endothelial growth factor (VEGF)-A induced neovascularization, we observed an 
11-fold increase in the cornea. Importantly, VEGF-A–induced chemotaxis of PTK7+ cells was 
mediated by VEGF receptor (VEGFR) 2. In a co-culture with endothelial cells, PTK7+CD11b+ 
cells stabilized the vascular network for 2 weeks by expressing high levels of angiopoietin-1 
(ANG-1). The enhanced vascular stability was abolished by knockdown of ANG-1 in 
PTK7+CD11b+ cells and could be restored by ANG-1 treatment.
Conclusions—We conclude that PTK7 expression in perivascular mononuclear cells induces 
VEGFR2 and ANG-1 expression, and thus contributes to vascular stabilization in angiogenesis.
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Introduction
Angiogenesis is a multifactorial process in which different cell types are involved, especially 
vascular endothelial cells (VEC), pericytes, fibroblasts, and bone marrow (BM)-derived 
cells.1–3 A variety of immune cells directly support angiogenesis, including mast cells, 
tumor-associated macrophages (TAMs), and Tie2-expressing macrophages (TEMs).4–6 
Endothelial cells recruit inflammatory cells to the extravascular tissue due to their 
expression of different leukocyte adhesion molecules. In turn, immune cells produce soluble 
factors, such as chemokines, cytokines, and proteases, that bind to endothelial cells and 
influence their function and angiogenesis in a paracrine fashion.4 Other studies have shown 
that BM-derived cells have the ability to differentiate into endothelial cells, possibly by 
conversion first to endothelial progenitors.6, 7
Interestingly, several lines of evidence suggest the presence of other types of BM derived 
circulating progenitor cells that do not incorporate directly into vessel formation, but 
promote vascular stabilization.8, 9 These BM derived perivascular cells interact with and 
support endothelial cells in the blood vessels,10, 11 indicating the importance of endothelial 
progenitor cells (EPC) and supporting cells to vasculature stabilization. Because the exact 
cellular markers and functions of these supporting cells and how they are mobilized and 
recruited into the angiogenic area remain unknown,12–15 it is of great interest to characterize 
circulating progenitor cells and their capacity to support the formation of vascular networks.
The pseudokinase protein tyrosine kinase 7 (PTK7) is an atypical tyrosine kinase receptor 
that lacks catalytic activity in its kinase domain.16 PTK7 regulates cell migration 
polarity,17–19 T cell maturation, migration of BM-derived cells,20 and endothelial cell 
migration as well as proliferation during angiogenesis.21, 22 We have recently provided 
evidence for an interaction between PTK7 and VEGFR1 (Flt-1) leading to enhanced 
migration of VECs.22 PTK7 is expressed by circulating mononuclear and leukemic cells, 
and mediates their pro-migratory and anti-apoptotic effects.20, 23 Moreover, numerous EPC 
marker studies have highlighted that hematopoietic (VEGFR1+) cells interact with 
endothelial (VEGFR2+) BM-derived progenitor subsets to induce and progress 
angiogenesis.7, 24, 25 Although PTK7 is expressed by peripheral blood mononuclear cells 
(PBMCs) and it interacts with VEGFRs, the specific function of PTK7+ blood cells in 
angiogenesis has not been thoroughly investigated.
In this study, we examined the role of PTK7+ mononuclear cells in angiogenesis in vitro and 
in vivo using a VEGF-A micropellet implantation model. We show that BM-derived PTK7+ 
cells recruited into the cornea in response to VEGF-A are CD11b+ mononuclear cells. More 
importantly, PTK7+CD11b+ mononuclear cells express high levels of VEGFR2 and 
angiopoietin-1 and are involved not only in neovascularization, but also new vessel 
stabilization.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement I and II.
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Results
PTK7+ mononuclear cells are recruited to the site of new vessel formation
The main experiments of this study are schematically illustrated in Figure 1A. To investigate 
the ingress and localization of PTK7+cells in the cornea over time, we used an in vivo 
corneal micropocket angiogenesis model (Figure 1A). We found newly formed PECAM-1+ 
(also known as CD31+) blood vessels as early as postoperative day 3 (POD 3) after 
micropellet implantation surgery and a peak vessel growth at 7 days after VEGF-A 
micropellet implantation (white arrow in Figure 1B, upper panel). Interestingly, a number of 
PTK7+ cells (white arrowhead) localized near the angiogenic area (Figure 1B, middle 
panel). The population of PTK7+ cells peaked on day 2 in the cornea, was maintained until 
day 5, and then decreased (Supplement III). Using confocal microscopy we found that 
PTK7+ cells were scattered near the vascular branching area, as well as attached to new 
vessels (Figure 1C; white arrows indicate PECAM+ cells, white arrowheads indicate PTK7+ 
cells; and Supplement IV). However, most PTK7+ cells, located near the angiogenic area, 
did not express the VEC marker PECAM-1, and were not incorporated into new vessels 
(Figure 1B, C, and Supplement V, video clip).
Next, we analyzed PTK7+ cells in the BM, peripheral blood, and cornea in VEGF-A 
micropellet-implanted mice using flow cytometry. In the BM and peripheral blood PTK7+ 
frequencies remained similar (Figure 1D and E; p=0.662 for BM and p=0.085 for PBMC, 
Students t-test) (Supplement VI). But, in the cornea PTK7+CD45+ and PTK7+CD11b+ cells 
were increased significantly 3 and 7 days after stimulation of angiogenesis (p<0.001, 
Students t-test; Figure 1F), indicating that the PTK7+ cells in angiogenic area are PTK7+ 
CD11b+ and PTK7+CD45+mononuclear cells.
VEGFR2 upregulation on PTK7+ cells promotes VEGF-A-mediated cell migration
VEGFR2 plays a crucial role in vasculogenesis, angiogenesis, and hematopoiesis, and is 
considered as one of the most definitive EPC markers.26, 27 To address whether the 
recruitment of PTK7+ cells to the cornea is associated with angiogenesis, we investigated 
the expression of VEGFR2 on PTK7+ cells during VEGF-A-induced angiogenesis using the 
corneal micropellet implantation model. Before micropellet implantation (day 0), 0.9% of 
cells express VEGFR2 in PBMCs, but the frequencies of VEGFR2+PTK7+ CD11b+ cells 
increased ~4.6-fold 7 days after VEGF-A pellet implantation (0.9% to 4.1% on day 7) 
(Figure 2A). Interestingly, most of the VEGFR2+ cells were positive for PTK7+ (Figure 2A 
and B). Seven days after micropellet implantation (POD7), 20.8% of PTK7+CD11b+ cells 
expressed VEGFR2. But, only 6.1% of PTK7−CD11b+ cells were VEGFR2+ at 7 days after 
the implantation (Figure 2B). The frequencies of VEGFR1+ cells did not differ between 
PTK7+CD11b+ and PTK7−CD11b+ cells (Figure 2C).
Next, we determined VEGFR2 expression of in vitro VEGF-A–stimulated PTK7+ and 
PTK7− CD11b+ PBMCs using flow cytometry and western blot. Similar to our in vivo data, 
VEGFR2 expression was increased only in PTK7+CD11b+ cells but not in PTK7−CD11b+ 
cells after VEGF-A stimulation (Figure 2D and E). Before in vitro treatment with VEGF-A, 
the mean frequencies of VEGFR2+ cells among PTK7−CD11b+ and PTK7+CD11b+ cells 
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were 1.1% (0.3~2.1) and 2.8% (1.9~4.5%), respectively (p=0.014, data not shown). 
However, treatment of VEGF-A for 36 hours increased the VEGFR2 expression to 34.5% in 
PTK7+CD11b+ cells (Figure 2D, lower panel). In PTK7−CD11b+ cells VEGF-A treatment 
did not change the frequencies of VEGFR2 expression (Figure 2D, upper panel). To confirm 
the role of PTK7 in VEGFR2 induction, PTK7 siRNA was transfected into PTK7+CD11b+ 
cells, and the expression of VEGFR2 was measured after 24 hours of VEGF-A treatment. 
Interestingly, VEGF-A induced VEGFR2 expression in PTK7+CD11b+ cells was reduced 
when PTK7 was downregulated (Figure 2E). Additionally, we observed a VEGF-A 
dependent VEGFR2 increase in PTK7+ but not PTK7− cells using western blot (Figure 2E 
and 2F).
To analyze VEGFR2 activity, we measured VEGFR2 receptor phosphorylation in 
PTK7+CD11b+ cells. Treatment with VEGF-A significantly enhanced VEGFR2 
phosphorylation in PTK7+CD11b+, but not PTK7−CD11b+ cells, in a dose-dependent 
manner (Figure 2G). In angiogenesis, VEGFR2 is critical for VEGF-A–mediated 
chemotaxis of EPCs into the area where the angiogenic process is initiated.26 Thus, we next 
analyzed whether VEGF-A treatment of PTK7+CD11b+ cells enhances their migratory 
potential using a transwell system. VEGF-A treatment significantly increased the migration 
of PTK7+CD11b+ cells, but not PTK7−CD11b+ cells. At 24 hours after treatment start, there 
was 8-fold increase of migration of PTK7+CD11b+ cells compared to PTK7−CD11b+ cells 
(Figure 2H).
Induction of VEGFR2 expression on PTK7+ cells depends on Nuclear Factor (NF)-κB 
activation by VEGF-A
We next investigated which signals upregulate VEGFR2 in PTK7+ cells in vitro. We sorted 
CD11b+ PTK7+ and CD11b+ PTK7− cells from PBMCs, treated them with VEGF-A and 
then analyzed mRNA and protein expression of VEGFR2 (Figure 3A). Seven days after 
micropellet implantation, VEGFR2 mRNA expression was 8.9 times higher in 
PTK7+CD11b+ than in PTK7−CD11b+ cells upon in vitro stimulation with 15ng/ml VEGF-
A (Figure 3B). Given that PTK7+ cells constitutively express VEGFR1 and regulate 
VEGFR1 signaling in mononuclear cells,22 we postulate that PTK7 expression affects 
VEGFR2 expression through VEGFR1 signaling. Indeed, increased VEGFR2 expression 
induced by VEGF-A could be inhibited using a VEGFR1 blocking antibody, implying that 
VEGF-A binding to VEGFR1 mediates VEGFR2 expression in PTK7+ cells (Figure 3B).
To define the mechanisms underlying PTK7-mediated VEGFR2 upregulation, we used 
signal transduction inhibitors and evaluated their effect on vegfr2 mRNA expression in 
PTK7+CD11b+ cells. Only SN50, a well-known NF-κB inhibitor, but no other inhibitors, 
significantly suppressed vegfr2 mRNA expression (Figure 3C). Similarly, VEGFR2 protein 
expression was inhibited only by SN50 as analyzed via Western Blot (Figure 3D) and flow 
cytometry (Figure 3E). In addition, RAW-264.7 cells were transfected with PTK7 siRNA, 
and transcription regulator activities were determined in response to VEGF-A stimulation. 
Compared with control siRNA (siCON), PTK7 siRNA (siPTK7)-treated RAW-264.7 cells 
showed significantly decreased NF-κB activities (Figure 3F) and IκB phosphorylation 
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(Figure 3G). These data indicate that VEGF-A activates NF-κB via VEGFR-1 and thus 
induces VEGFR-2 expression in PTK7+ cells.
PTK7+ mononuclear cells facilitate vessel stabilization in vitro
Our results showed that PTK7+ mononuclear cells express VEGFR2 and respond to VEGF-
A, and thus may play a significant role in corneal angiogenesis. We used the matrigel assay 
to determine the exact role of PTK7+ cells in angiogenesis in vitro. When VECs were 
cultured alone, the tube-like structures formed at 3 hours and matured at 18 hours, after 
which the vascular networks began to disappear and simple Y- or T-shaped branch 
structures remained (Figure 4A). When PTK7−CD11b+ cells isolated from micropellet 
implanted mice were co-cultured with VECs, we did not find tube-like structures. Instead, 
we observed only small cell-to-cell contacts or branch-like structures (Figure 4A). 
Interestingly, VECs that were co-cultured with PTK7+CD11b+ cells from micropellet 
implanted mice developed tube-like structures, matured in a time-dependent manner, and 
were stable for 2 weeks (Figure 4A, B, and C).
In Figure 4D we show VECs co-cultured with PTK7+CD11b+ cells from 6 hours for up to 9 
days. Six hours after starting the assay we observed round PBMCs accumulating close to the 
VECs (Figure 4D, upper left panel, black box). At 24 hours round PBMCs (upper center 
panel, white arrow) gathered closer to VECs (upper right panel, white arrowhead). Next, 
network-like structures developed and matured within 72 hours. During the elongation of the 
vascular network, migratory myeloid cells were found near the vascular network (Figure 4D, 
middle row), which were attached to the growing tubes (Figure 4D, middle right panel, 
white arrows). These myeloid-like cells were sometimes linearly attached to each other, and 
were found near the blood vessels (middle left panel, white arrows, Figure 4D). This well-
formed reticular vascular network was stable for up to 9 days. To determine whether 
VEGFR2 expression is able to facilitate tube formation and its stability, we knocked down 
VEGFR2 in a tube formation assay. After confirming a successful knock down of VEGFR2 
in PTK7+CD11b+ cells by siVEGFR2 transfection (siR2) (Figure 4E), we co-cultured these 
cells with VECs as described above. VEC tube formation was significantly reduced when 
cocultured with siVEGFR2-transfected compared to random siRNA (Rsi)-transfected 
PTK7+CD11b+ cells (Figure 4E). This result confirms that VEGFR2 expression is crucial 
for vascular network formation.
PTK7+ mononuclear cells enhance vascular stability through angiopoietin-1 secretion
Based on our previous results, we hypothesized that PTK7+ cells have the potential to 
stabilize vessel formation. To clarify the specific angiogenic functions of PTK7+ 
mononuclear cells, we sorted CD11b+PTK7+ and CD11b+PTK7− cells from PBMCs, BM, 
or corneas 3 days after micropellet implantation (Figure 5A). We first compared mRNA 
expression of various angiogenic markers in sorted PTK7− and PTK7+ cells. mRNA 
expression of vegfr2, angiopoietin-1 (ANG-1), neurophilin 1 (NRP1), apelin (APLN), and 
delta-like 4 (DLL4) were significantly higher in PTK7+ than in PTK7− cells (Figure 5B). 
mRNA expression of ang-1 was significantly increased in PTK7+ compared with PTK7− 
cells isolated from BM, PBMC, and cornea (CO) (Figure 5C). Protein expression of ANG-1 
was also significantly elevated in PTK7+ cells compared with PTK7− cells, whereas 
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angiopoietin-2 (ANG-2) expression showed no significant difference between PTK7+ and 
PTK7− cells (Figure 5D). To analyze whether the ANG-1 production of PTK7+ cells needs 
direct VEC interaction or not, we used a PTK7+CD11b+/VEC mixed culture (MC) or the 
Boyden Chamber (BC), respectively. ANG-1 secretion from PTK7+ cells (Figure 5E) and 
subsequent phosphorylation of Tie2, a known receptor for ANG-1 (Figure 5F) was similar 
using the mixed culture and Boyden Chamber. These observations indicate that the presence 
of PTK7 itself is responsible for ANG-1 secretion in mononuclear cells. As ANG-1 is a 
well-known mediator secreted by pericytes to recruit VECs and promote vascular 
stability,12, 28 PTK7+ cells may stabilize vessel formation via ANG-1 secretion. Thus, we 
investigated the functional role of ANG-1 in PTK7+ cells. Indeed, PTK7+CD11b+ and VEC 
co-cultures treated with siRNA for ANG-1 (siANG-1) displayed less angiogenesis. 
Moreover, treatment with exogenous ANG-1 protein rescued vascular network formation in 
a co-culture condition with PTK7 knock-downed cells (Figure 5G). These data suggest that 
PTK7+ cells represent a subpopulation of BM-derived mononuclear cells that mediate 
vascular stabilization through ANG-1 production.
Discussion
In this study, we show for the first time that (i.) during early angiogenesis, increased 
frequencies of PTK7+ mononuclear cells are recruited to the angiogenic site, where they 
closely communicate with VECs and enhance vascular growing and stability; (ii.) VEGFR2 
expression is significantly higher in PTK7+ mononuclear cells compared to PTK7− cells, 
and this expression is induced by VEGF-A through VEGFR1-mediated NF-κB activation; 
and (iii.) PTK7+ cells upregulate the expression of the angiogenic mediator ANG-1 and 
contribute to vascular stability. The main findings of this study are schematically illustrated 
in Figure 6.
Although the knowledge about EPCs has increased, the phenotypic and functional 
characterization of EPCs is hampered by the extreme rarity of these cells, controversial 
studies regarding surface marker expression, and the absence of standard in vitro or in vivo 
assays to characterize their function.29, 30 Nevertheless, EPCs are most commonly identified 
as CD133+CD34+VEGFR2+, CD45dimCD34+VEGFR2+, CD14+CD34low, and 
CD11b+VEGFR2+ cells.31 Because VEGFR2 is the only surface marker shared by all 
studies to identify EPCs, we focused on VEGFR2 expression by PTK7+ mononuclear cells 
in our study. Moreover, VEGFR2 contributes to angiogenesis and promotes endothelial cell 
migration and proliferation.
Here, we demonstrate that PTK7+ CD11b+ PBMCs express significantly higher amounts of 
VEGFR2 after angiogenic stimulus. Interestingly, not only CD11b+ cells, but also F4/80+ 
PBMCs showed higher PTK7 expression in VEGFR2+ cells, compared with 
VEGFR2−F4/80+ cells. (Supplement VII). PTK7 has previously been shown to interact with 
VEGFR1 in a VEGF-A-specific manner to enhance angiogenesis in VECs.22 Ohki and 
colleagues have reported that CD45+CD11b+VEGFR1+ cells egress from the BM after 
injury, and these cells display EPC characteristics.32 They also found that 50% of the 
CD11b population expresses VEGFR1, and that these cells show a 5-fold increased 
revascularization activity, compared to CD11b+ VEGFR1− cells. Interestingly, we found 
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that most VEGFR2+CD45+ cells (96.4%) express VEGFR1. In addition, PTK7+CD11b+ 
cells express higher VEGFR2 levels than PTK7−CD11b+ cells, suggesting that VEGFR1 
may be a prerequisite factor for VEGFR2 expression through a PTK7-mediated pathway.
While splenic PTK7+ and PTK7− cells express similar amounts of VEGFR2 mRNA, PTK7+ 
cells in the cornea or blood express significantly increased levels of VEGFR2 compared to 
PTK7− cells, which can be further increased by VEGF-A pellet insertion (Supplement VIII), 
indicating that VEGFR2 acquisition occurs in a site-specific manner, suggesting that other 
factors (e.g., neural, neighbor cells and matrix proteins) also affect the development of 
EPCs. A recent study demonstrated that VEGFR2 expression promotes EPC egression from 
the BM into peripheral blood.13 SDF-1/CXCR4 axis disruption induced CD11b+CD45+ BM 
cell mobilization. 33–35 However, Pitchford et al reported that VEGF-A activates EPC 
mobilization through VEGFR2, and not VEGFR1 or the SDF-1/CXCR4 axis,13 suggesting 
that VEGFR2 expression on PTK7 cells in BM EPCs may be critical for EPCs to egress 
from the BM into peripheral blood.
EPC-induced angiogenesis is a complex process that causes EPCs to migrate to the wound 
site. We propose that the PTK7+VEGFR2+ cells we characterized in our study are similar to 
“early-outgrowth cells” that are descendants of a monocyte-macrophage subset, and play a 
role in blood vessel homeostasis and angiogenesis initiation during wound healing and tissue 
ischemia.14, 36 These “early-outgrowth cells” express CD45 and other mononuclear cell 
markers (e.g., CD11b or CD14), fail to proliferate, and are defined as perivascular cells 
rather than lumen-lining cells. These cells act by secreting angiogenic factors and enzymes 
that can degrade the matrix.37–39 Similarly, PTK7+ cells primarily express mononuclear cell 
markers and do not display proliferative activity (data not shown). More importantly, PTK7+ 
cells are found in and around newly growing blood vessels in a scattered pattern, where they 
palisade along the growing vessels and aggregate into a blind-ended capillary-like structure. 
PTK7+ PBMCs express specific pericyte markers, including ANG-1, PDGF-β, and desmin 
(supplement IX), but not the tip cell marker CD34 (Figure 5). Since perivascular localized 
cells, which express ANG-1, PDGFR-β, and CD13 are considered as pericytes,10, 40 PTK7+ 
cells may function similar to classic pericytes, stabilizing vascular networks by modifying 
the environment and hence stabilizing tubular structures.
ANG-1 treatment may reduce vascular leakage, inhibit VEC apoptosis, and enhance 
vascular stability, branching, and remodeling of an immature vessel plexus into a more 
complex network.28, 41–43 ANG-1 expression from BM cells appears to have a critical role 
in angiogenesis, pericyte recruitment, and vascular stabilization.12, 28, 44 Our findings show 
that PTK7+ cells highly express ANG-1 and that the vascular stability of VECs is ANG-1 
dependent (Figure 5), suggesting that PTK7+CD11b+ cells supply ANG-1 to the angiogenic 
area to promote vascularization at an early angiogenic time point.
In summary, this study highlights the relevance of PTK7 expression by mononuclear cells in 
promoting VEGF-A–mediated angiogenesis. Our data suggest that PTK7 amplifies the 
expression level of VEGFR2 on these cells, which is an important step in the initial phase of 
angiogenesis. Thus, targeting PTK7 in BM-derived mononuclear cells may provide an 
effective strategy in treating angiogenesis-related disorders.
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Nonstandard Abbreviations and Acronyms
PTK7 protein kinase 7
ANG-1 angiopoietin-1
EPC endothelial progenitor cells
VEC vascular endothelial cell
BM bone marrow
PBMC peripheral blood mononuclear cells
Abbreviation
PTK7 protein kinase 7
ANG-1 angiopoietin-1
EPC endothelial progenitor cells
VEC vascular endothelial cell
BM bone marrow
PBMC peripheral blood mononuclear cells
VEGFR vascular endothelial growth factor receptor
VEGF vascular endothelial growth factor
POD postoperative day
NF-kB Nuclear factor-kappaB
siCON Control siRNA (si: small interfering)
siR2 VEGFR2 siRNA
ANG angiopoietin
NRP neurophilin
Chauhan et al. Page 8
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Dll4 Delta like 4
SDF-1 stromal cell-derived factor 1 (SDF-1)
UNC5B unc-5-homolog B
PLXND1 plexin D1
BC Boyden chamber
MC Mixed culture
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Significance section
In this study, we show for the first time that (i.) during early angiogenesis, increased 
frequencies of PTK7+ mononuclear cells are recruited to the angiogenic site, where they 
closely communicate with VECs and enhance vascular growing and stability; (ii.) 
VEGFR2 expression is significantly higher in PTK7+ mononuclear cells compared to 
PTK7− cells, and this expression is induced by VEGF-A through VEGFR1-mediated NF-
κB activation; and (iii.) PTK7+ cells upregulate the expression of the angiogenic 
mediator ANG-1 contributing to vascular stability.
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Figure 1. PTK7+ cells recruit to the cornea after VEGF-A-induced neovascularization
A, Schematic drawing illustrates the VEGF-A micropellet-induced corneal angiogenesis 
experiment. To induce corneal neovascularization VEGF-A (160 μg) micropellets were 
inserted into Balb/c mouse corneas (n=5). Corneas were harvested before micropellet 
implantation (day 0) and at postoperative day (POD) 3 and 7. B and C, Corneas were 
isolated at postoperative day (POD) 3 and 7, immunohistochemically stained for PECAM-1 
(green) and PTK7 (red), and then examined by epifluorescence microscopy (× 200) (B) and 
confocal microscopy (C); white arrows indicate new vessels, arrowheads indicate PTK7+ 
cells. D, Representative flow cytometry histogram showing the percentage of PTK7+ cells in 
the bone marrow (BM) before (Control) and 7 days after micropellet implantation (POD7). 
E and F, Representative flow cytometry dot plots showing PTK7+CD45+ (upper row) and 
PTK7+CD11b+ (lower row) cells in peripheral blood mononuclear cells (PBMCs) (E) and 
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cornea (F) before micropellet implantation (Control), and 3 (POD3) and 7 days (POD7) after 
implantation.
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Figure 2. VEGFR2 expression and migration of PTK7+ CD11b+ cells is induced by VEGF-A
VEGF-A corneal pellets were implanted in 6-week-old Balb/c mice (n=7) and mice were 
analyzed before implantation (Control, day 0) and at postoperative days (POD) 3 and 7. 
Peripheral blood mononuclear cells (PBMCs) were stained with monoclonal anti-mouse 
PTK7-PE-, CD11b-FITC-, and VEGFR2-APC-conjugated antibodies. Frequencies of 
VEGFR2+PTK7+ were measured in CD11b+ cells on POD 0, 3, and 7 using flow cytometry 
(A). VEGFR2- (B) and VEGFR1- (C) expression was compared between PTK7+CD11b+ or 
PTK7−CD11b+ cells by flow cytometry at POD 0, 3, and 7. D, Representative flow analysis 
histogram shows VEGFR2+ cell frequencies on PTK7+CD11b+ and PTK7−CD11b+ cells 
(1.2 x 105 cells/well) 24 and 36 hours after VEGF-A stimulation (20ng/ml). VEGFR2 
expression was measured by flow analysis. E, Expression of VEGFR2 by PTK7 siRNA 
(siPTK7) transfection was determined. After transfection of siPTK7 or random siRNA (Rsi), 
VEGF-A (20ng/ml) was treated for 24 hours then, the expression of VEGFR2 and phospho-
VEGFR2 was measured by immunoblot. F, PTK7−CD11b+ and PTK7+CD11b+ cells were 
stimulated with VEGF-A (20 ng/ml) for 0 to 36 hours and the expression of VEGFR2 
protein was measured by western blot. G. Phosphorylated VEGFR2 (Tyr951, 7H11) was 
compared between PTK7+CD11b+ and PTK7−CD11b+ cells by immunoblot at 1, 5, and 15 
minutes after VEGF-A stimulation (20 ng/ml). H, PTK7−CD11b+ (white dot) and 
PTK7+CD11b+ (black dot) PBMCs were separated using flow cytometry and cell migration 
was determined in a time-dependent manner using a transwell assay. 8×104 PTK7+CD11b+ 
and PTK7−CD11b+ PBMCs were seeded in the upper chamber, with or without VEGF-A 
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(20 ng/ml). The cells that migrated to the bottom of the lower chamber were stained with 
hematoxylin and counted using an inverted microscope. All experiments were repeated four 
times. Data are expressed as the mean ± standard deviation. *p < 0.05; **p < 0.01.
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Figure 3. Enhanced VEGFR2 expression in PTK7+ cells is Nuclear Factor (NF)-κB dependent
A, A schematic illustration showing how PTK7+ and PTK7− cells from peripheral blood 
mononuclear cells (PBMCs) were separated from VEGF-A pellet-implanted mice using 
FACS. B, Vegfr2 mRNA expression in PTK7+ and PTK7− cells was measured by real-time 
qPCR 12 hours after VEGF-A treatment in the absence or presence of 10μM anti-VEGFR1 
neutralizing antibody or IgG isotype control antibody. C–E, PTK7+ and PTK7− cells were 
treated with various signal transduction inhibitors (30 μM; SB: SB203580, LY: LY294002, 
PD: PD98059, RP: Rapamycin, SM: SN50M, and SN: SN50) 30 minutes before VEGF-A 
(30 ng/ml) stimulation and then VEGFR2 mRNA (C), protein levels (D), and surface 
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expression levels (E) were determined. F, PTK7 siRNA- or control siRNA-transfected 
PTK7+CD11b+ cells were cultured with VEGF-A. Two hours after incubation in 10% 
RPMI, the cells were transfected with NF-κB luciferase constructs for 12 hours. Following 
30 minutes of VEGF-A treatment, cells were lysed, and luciferase activities were measured 
using a luminometer. All data are representative for four independent experiments and are 
expressed as the mean ± standard deviation. **p < 0.01. G, Control siRNA (siCon) or PTK7 
siRNA (siPTK7)-transfected cells were treated with VEGF-A (20 ng/ml) as indicated, and 
western blot was performed using anti-phospho-IκB and anti-IκB antibodies.
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Figure 4. PTK7+ mononuclear cells facilitate vessel growth and stability in vitro
A, The tube formation assay was performed using a mouse vascular endothelial cell (VEC) 
line (MS1) and PTK7+ or PTK7− CD11b+ peripheral blood mononuclear cells (PBMCs;). 
Images were obtained using an inverted microscope at 11 days later (×2 and ×10: objective 
lens magnification). B and C, Five high-magnification (200×) pictures for each condition 
were taken, and the tube length (B), and branching (C) were measured using image analysis 
software. *p < 0.05 vs. PBMC, **p < 0.01 vs. PBMC. (VEC: vascular endothelial cell, 
PTK7−: PTK7−CD11b+, PTK7+: PTK7+CD11b+). The results are mean ± SD from three 
independent experiments. D, VECs were co-cultured with PTK7+ or PTK7− PBMCs and 
images were taken as early as 6 h and up to 9 days after starting the coculture. White arrows 
in the upper center panel (6 hours) indicate palisading PBMCs (black box, upper row). The 
white arrowheads in the upper right panel indicate new vessel buds growing from clusters of 
endothelial cells at 24 hours. Linear or palisading PBMCs were found near the growing 
vascular network (white arrows in the middle left panel; 72 hours). Cells with hair-like long 
processes were observed at the end of the blood vessels (white arrows in the middle center 
and middle right panel). Macrophage-like cells were linked to growing endothelial buds and 
the tips of the growing tubes (black box, lower row). A stable vascular network was 
observed up to 9 days after culture. E, PTK7+CD11b+ PBMCs were transfected with 
random siRNA (Rsi) or siVEGFR2 (siR2) and VEGFR2 expression levels was determined 
by immunoblot at 72 hours after transfection. Then, VEGFR2 knock down PTK7+CD11b+ 
cells were cultured with VECs for the tube formation assay. 14 days later we observed less 
tube formation in VECs when co-cultured with VEGFR2 knock down cells.
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Figure 5. PTK7+ cells enhance vascular stability through angiopoietin-1
A, A schematic drawing illustrates experiments for Figure 5A–E. B, Real-time qPCR 
analysis showing the expression of VEC markers in PTK7+CD11b+ and PTK7−CD11b+ 
cells. Comparison of the expression of N: GAPDH to the expression of empty pellets of 
vascular endothelial cell growth factor receptor (VEGFR) 2, Angiopoietin 1 (ANG-1), 
Neurophilin 1 (NRP1), Apelin (APLN), Delta-like 4 (DLL4), Ephrine B2 (EPHRIN B2), 
VEGFR1, unc-5-homolog B (UNC5B), CXCR4, plexin D1 (PLXND1), Neuropilin-2 
(NRP-2), and CD34 was done. C, Three days after pellet insertion PTK7+CD11b+ and 
PTK7−CD11b+ cells were sorted by FACS from the bone marrow (BM), peripheral blood 
mononuclear cells (PBMC), and cornea. mRNA expression of ANG-1 was assessed using 
real-time qPCR. The fold increase compared to non-operated control mice was measured. D, 
Protein expression of ANG-1 and ANG-2 of in vitro cultured PTK7−CD11b+ and 
PTK7+CD11b+cells measured by ELISA after 24 hours of VEGF-A (40ng/ml) treatment. E 
and F, 5 × 104 PTK7+CD11b+ cells were cultured with 2 × 105 vascular endothelial cells 
(VECs) using a Boyden chamber (BC) or a mixed co-culture (MC). ANG-1 protein 
concentration (E) and phospho-Tie2 and total Tie2 (F) were measured by ELISA or 
immunoblot, respectively, 24 hours later. G, PTK7+CD11b+ cells were sorted and 
transfected with random siRNA (Rsi), siANG-1, siANG-2, or siPTK7. Then, cells were co-
cultured with VECs in a matrigel for 5 days. As indicated 2 co-culture conditions of siPTK7 
transfected cells and VECs were treated with 40ng/ml of ANG-1 or ANG-2 every 24 hrs. 
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All experiments were repeated four times. Data are expressed as the mean ± standard 
deviation. *p < 0.05; **p < 0.01.
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Figure 6. Proposed mechanism for the role of PTK7+VEGFR2+ mononuclear cells in 
angiogenesis
PTK7 expression by mononuclear cells is necessary for VEGFR2 acquisition in bone 
marrow and peripheral blood. These PTK7+VEGFR2+ mononuclear cells migrate to 
angiogenic sites where they promote angiogenesis by up-regulating ANG-1 secretion. Given 
their topographic localization and expression markers, they likely function in stabilizing 
blood vessel formation and/or have EPC potential.
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